Tenaya Therapeutics (TNYA) grants RSUs and 175,500 stock options to SVP Finance
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Tenaya Therapeutics, Inc. granted new equity awards to SVP, Finance Tomohiro Higa. On February 3, 2026, he received 29,250 shares of common stock in the form of restricted stock units, issued at $0 and bringing his directly held common stock (including unvested RSUs) to 123,221 shares.
Higa also received a stock option for 175,500 shares of common stock with an exercise price of $0.915 per share, expiring on February 2, 2036. The option vests in equal monthly installments over 48 months starting one month after the grant date, while the new RSUs vest in eight equal installments every six months beginning August 15, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Higa Tomohiro
Role
SVP, Finance
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) | 175,500 | $0.00 | -- |
| Grant/Award | Common Stock | 29,250 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to buy) — 175,500 shares (Direct);
Common Stock — 123,221 shares (Direct)
Footnotes (1)
- Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2026, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. Includes 79,720 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.
FAQ
What equity awards did Tenaya Therapeutics (TNYA) grant to Tomohiro Higa?
Tenaya Therapeutics granted Tomohiro Higa 29,250 restricted stock units of common stock and a stock option for 175,500 shares with an exercise price of $0.915 per share, all under the company’s 2021 Equity Incentive Plan.
How do the new RSUs for TNYA executive Tomohiro Higa vest?
The 29,250 RSUs granted to Tomohiro Higa vest over four years. One-eighth vests on August 15, 2026, and an additional one-eighth vests every six months thereafter until the award is fully vested, assuming continued service.
What is the vesting schedule for Tomohiro Higa’s 175,500 TNYA stock options?
The 175,500 stock options vest in 48 equal monthly installments. Vesting starts on the one-month anniversary of the February 3, 2026 grant date and continues monthly until fully vested, with an expiration date of February 2, 2036.
What is Tomohiro Higa’s total TNYA common stock ownership after this Form 4?
After these grants, Tomohiro Higa beneficially owns 123,221 shares of Tenaya Therapeutics common stock directly, including 79,720 shares that will be issued upon vesting of previously granted restricted stock units, plus separate options for 175,500 shares.
At what price can Tomohiro Higa exercise his new Tenaya Therapeutics stock options?
Tomohiro Higa’s newly granted stock option allows him to purchase 175,500 Tenaya Therapeutics shares at an exercise price of $0.915 per share. The option was granted on February 3, 2026 and remains exercisable until its February 2, 2036 expiration.
Are Tomohiro Higa’s new Tenaya Therapeutics awards direct or indirect holdings?
Both the 29,250 RSUs and the 175,500 stock options are reported as held directly by Tomohiro Higa. The filing does not indicate any indirect ownership through entities or family members for these specific awards.